Dept of Pharma Launches New Marketing code For Drugs Stirs Debate

The department of pharmaceuticals (DoP) has framed with another arrangement of rigid marketing code for the pharma organizations. Uniform Code for Drug Showcasing Practices (UCPMP) 2024 is the new code and is “mandatory” and would supplant the...

IIT Guwahati Pioneers Groundbreaking Vaccine for Swine Fever

The Indian Institute of Technology Guwahati has achieved a significant milestone by successfully transferring a groundbreaking vaccine technology to BioMed Pvt. Ltd., a renowned manufacturer specializing in high-quality vaccines. This innovative ...

Verge Genomics and Ferrer Team up To co-develop Clinical-stage ALS Therapy

Verge Genomics, a leading biotechnology firm, has declared a partnership with Ferrer to co-foster VRG50635, Verge’s lead candidate, for the treatment of irregular and familial types of amyotrophic lateral sclerosis (ALS) in Europe, Central and...

Baby Memorial Launches 'Continuous Connected Care@BMH' Initiative with Dozee

Baby Memorial Hospital, Kozhikode, a venerable institution with over three decades of unwavering commitment to accessible and quality healthcare, announces the launch of the ‘ContinuousConnectedCare@BMH’ initiative. In a pioneering move, all ward...

Wipro GE Healthcare To Fund Rs 8,000 Crore on Manufacturing and R&D

Wipro GE Healthcare services declared funding of more than $1 billion (Rs 8000 crore) in manufacturing results and nearby research and development (R&D) for the next five years. This essential speculation supports Wipro GE Healthcare’s local...

AstraZeneca's Ultomiris Bags US FDA Nod to Treat Adults with NMOSD

AstraZeneca's Ultomiris (ravulizumab-cwvz) has been sanctioned in the United States as the initial and long-acting C5 supplement inhibitor for the treatment of grown-up patients with anti- aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis...

© 2024 India Pharma Outlook. All Rights Reserved.